127 related articles for article (PubMed ID: 37270213)
1. The flaws in assessing and reporting the toxicities of oral targeted therapies: Everolimus as an example.
Fojo T
Semin Oncol; 2023; 50(1-2):1-6. PubMed ID: 37270213
[No Abstract] [Full Text] [Related]
2. Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients.
Lo Muzio L; Arena C; Troiano G; Villa A
Oral Dis; 2018 Mar; 24(1-2):144-171. PubMed ID: 29480626
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors.
Zhu M; Molina JR; Dy GK; Croghan GA; Qi Y; Glockner J; Hanson LJ; Roos MM; Tan AD; Adjei AA
Invest New Drugs; 2020 Dec; 38(6):1755-1762. PubMed ID: 32328844
[TBL] [Abstract][Full Text] [Related]
4. Everolimus therapy and side‑effects: A systematic review and meta‑analysis.
Arena C; Bizzoca ME; Caponio VCA; Troiano G; Zhurakivska K; Leuci S; Lo Muzio L
Int J Oncol; 2021 Jul; 59(1):. PubMed ID: 34132370
[TBL] [Abstract][Full Text] [Related]
5. Common toxicities of mammalian target of rapamycin inhibitors.
Soefje SA; Karnad A; Brenner AJ
Target Oncol; 2011 Jun; 6(2):125-9. PubMed ID: 21499766
[TBL] [Abstract][Full Text] [Related]
6. Clinical Response to Everolimus of EGFR-Mutation-Positive NSCLC With Primary Resistance to EGFR TKIs.
Matsuoka H; Kaneda H; Sakai K; Koyama A; Nishio K; Nakagawa K
Clin Lung Cancer; 2017 Jan; 18(1):e85-e87. PubMed ID: 28341110
[No Abstract] [Full Text] [Related]
7. Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma.
Bendtsen MAF; Grimm D; Bauer J; Wehland M; Wise P; Magnusson NE; Infanger M; Krüger M
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28796163
[TBL] [Abstract][Full Text] [Related]
8. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
Xu J; Tian D
Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
[TBL] [Abstract][Full Text] [Related]
9. Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma.
Jebali M; Elaidi R; Brizard M; Fouque J; Takouchop C; Sabatier B; Oudard S; Medioni J
BMC Cancer; 2017 Jan; 17(1):27. PubMed ID: 28061764
[TBL] [Abstract][Full Text] [Related]
10. Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast Cancer.
Rugo HS
Clin Breast Cancer; 2016 Feb; 16(1):18-22. PubMed ID: 26507507
[TBL] [Abstract][Full Text] [Related]
11. Risk of fatigue in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative meta-analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2015 Apr; 15(4):477-86. PubMed ID: 25665062
[TBL] [Abstract][Full Text] [Related]
12. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy.
Rozenblit M; Mun S; Soulos P; Adelson K; Pusztai L; Mougalian S
Breast Cancer Res; 2021 Jan; 23(1):14. PubMed ID: 33514405
[TBL] [Abstract][Full Text] [Related]
13. A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer.
Lolli C; Gallà V; Schepisi G; Barone D; Burgio SL; Maugeri A; Vertogen B; Amadori D; De Giorgi U
Oncologist; 2017 Jul; 22(7):784-e74. PubMed ID: 28546463
[TBL] [Abstract][Full Text] [Related]
14. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma.
Donskov F; Motzer RJ; Voog E; Hovey E; Grüllich C; Nott LM; Cuff K; Gil T; Jensen NV; Chevreau C; Negrier S; Depenbusch R; Bergmann L; Cornelio I; Champsaur A; Escudier B; Pal S; Powles T; Choueiri TK
Eur J Cancer; 2020 Feb; 126():1-10. PubMed ID: 31887537
[TBL] [Abstract][Full Text] [Related]
15. Clinical analysis of everolimus in the treatment of metastatic renal cell carcinoma.
Ren Z; Niu Y; Fan B; Wei S; Ma Y; Zhang X; Guo X; Zhang A
Ann Palliat Med; 2021 Jan; 10(1):584-589. PubMed ID: 33474959
[TBL] [Abstract][Full Text] [Related]
16. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C
Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551
[TBL] [Abstract][Full Text] [Related]
17. Stomatitis in mTOR inhibitors treatment and other targeted cancer therapy, possibilities of infl uencing it, and the use of local corticotherapy.
Vokurka S; Kozáková Š; Jánská V; Černá A; Liška J
Klin Onkol; 2020; 33(6):436-439. PubMed ID: 33685192
[TBL] [Abstract][Full Text] [Related]
18. Differences in adverse event profiles between everolimus and temsirolimus and the risk factors for non-infectious pneumonitis in advanced renal cell carcinoma.
Nozawa M; Ohzeki T; Tamada S; Hongo F; Anai S; Fujimoto K; Miki T; Nakatani T; Fukasawa S; Uemura H
Int J Clin Oncol; 2015 Aug; 20(4):790-5. PubMed ID: 25342378
[TBL] [Abstract][Full Text] [Related]
19. Erythema nodosum arising during everolimus therapy for tuberous sclerosis complex.
Galligan ER; Fix L; Levin LE; Imundo L; Yamashiro DJ; Garzon MC
Pediatr Dermatol; 2018 Jul; 35(4):e235-e236. PubMed ID: 29766561
[TBL] [Abstract][Full Text] [Related]
20. Everolimus-induced Chylous Effusion.
Kazzaz F; O'Connell OJ; Vial MR; Stewart J; Grosu HB
Am J Respir Crit Care Med; 2018 Jul; 198(1):120-122. PubMed ID: 29630393
[No Abstract] [Full Text] [Related]
[Next] [New Search]
